

1 **Evaluation of serological tests for detecting SARS-CoV-2 antibodies: implementation in**
2 **assessing post vaccination status**

3 **Running title: Evaluation of serological tests for detecting SARS-CoV-2 antibodies**

4 **Authors' details**

5 1.Dr. Sally A. Mahmoud (Corresponding author)

6 Biogenix Lab G42, Abu Dhabi, UAE

7 Email ID: sally.abdulla@g42.ai

8 2.Dr. Subhashini Ganesan

9 G42 Healthcare, UAE

10 Email ID: Subhashini.g@g42.ai

11 3.Mr. Shivaraj Naik

12 Biogenix Lab G42, Abu Dhabi, UAE

13 Email ID : shivaraj.Naik@g42.ai

14 4 Ms. Safaa Bissar

15 Biogenix Lab G42, Abu Dhabi, UAE

16 Email ID: Safaa.Bissar@g42.ai

17 5.Ms. Isra Zamil

18 Biogenix Lab G42, Abu Dhabi, UAE

19 Email ID: Isra.Zamil@g42.ai

20 6.Dr.Walid Abbas Zaher

21 G42 Healthcare, UAE

22 Email ID : Walid.Zaher@g42.ai

23

24

G42-Public

25 **Abstract**

26 **Background**

27 The anti-SARS-CoV-2 immunological assays have promising applications in the control and
28 surveillance of the current COVID-19 pandemic. Therefore, large number of serological
29 assays are developed in the commercial market to measure SARS-CoV-2 antibodies, which
30 requires evaluation before their application in large scale.

31 **Objectives**

32 To evaluate the performances of commercially available serological assays for detecting
33 SARS-CoV-2 antibodies.

34 **Methods**

35 The study compared the performances of six different methods for detection of antibodies
36 against SARS-CoV-2 which includes (i) Genscript SARS-CoV-2 surrogate virus
37 neutralization test kit [Test A] (ii) Diasorin - SARS-CoV-2 S1/S2 IgG detection [Test B] (iii)
38 Alinity SARS-CoV-2 IgG II [Test C] (iv) Diasorin – SARS-CoV-2 TrimericS IgG [Test D]
39 (v) Roche Elecsys Anti-SARS-CoV-2 – cobas [Test E] (vi) AESKULISA (AESKU Enzyme
40 Linked Immunosorbent Assay) [Test F] against the gold standard Plaque Reduction
41 Neutralization Test (PRNT).

42 **Results**

43 Test E had the highest sensitivity and Test A had the highest specificity The ROC for tests A,
44 C, D and E showed optimum cut-offs that differed from the manufacturer's recommendation.
45 Test D had the best performance considering all the performance indicators with the highest
46 agreement with the PRNT results. Parallel testing of test A with test D and test B had the
47 optimum performance.

48 **Conclusion**

49 Serological assays that are commercially available are very promising and show good
50 agreement with the standard PRNT results. Studies on large samples for optimization of the
51 assay cut-off values and cost-effective evaluations on parallel testing methods are needed to
52 make recommendations on these commercial assays.

53 **Importance**

54 Serological assays that are commercially available are very promising and this paper adds
55 new knowledge about the optimization of these kits for evaluating post vaccination antibodies
56 status. It highlights the positive and negative aspects of each of these assays in terms of
57 sensitivity, specificity, positive and negative predictive values, and the agreement of results
58 with the standard neutralization test. When serological assays are being used to assess post-
59 vaccine immune status, a balance of all parameters needs to be considered rather than
60 emphasizing only on high specificity. This is particularly relevant in the current situation
61 where vaccination is happening around the globe, high sensitivity assays will result in
62 reporting a lower percentage of false negative reports and avoids panic about lack of vaccine
63 response. It is important that we understand the strengths and limitations of commercially
64 available serological assays for better application of these tests to understand immune
65 response and the duration of protection post vaccination.

66 **Key words:** SARS-CoV-2; Serological assays; COVID-19; ELISA; CLIA

67 **Background**

68 The emergence of this global pandemic of COVID-19 has created an increased need for large
69 scale PCR testing and serological assays. Serological testing has enormous applications in
70 handling the current pandemic, it has both individual and population level practical
71 applications that can facilitate pandemic response. At the individual level it can help

G42-Public

72 differentiate recent and past infections of COVID-19, immune status post-vaccination to
73 study the need for booster doses and identifying vaccine intervals. At the population level it
74 helps study the epidemiology of SARS-CoV-2 pandemic, seroprevalence, and thereby help
75 public health experts make recommendations on travel, social distancing, and the protective
76 status of the population. [1] There are several serodiagnosis assay platforms that are being
77 used for COVID-19 infections: the FDA has issued emergency authorization for ELISA,
78 lateral flow immunoassay, and microsphere immunoassay. [2] These tests measure the
79 antibody to nucleocapsid N protein antigens and antibodies binding to SARS-CoV-2 spike
80 protein S, but not all spike-binding antibodies are functional or blocks viral infection, hence
81 they do not indicate the functional measure of the antibody that inhibits SARS-CoV-2
82 infection. Ideally, tests should measure the neutralizing antibodies, which implicate
83 protection from infection. The gold standard for measuring neutralizing antibodies is the
84 plaque reduction neutralization test (PRNT). PRNT is however not practical for large scale as
85 it requires skilled manpower, high-level biohazard security (BSL-3 level) and requires long
86 turnaround time of five days. [3,4]

87 Therefore, to address this gap, a lot of commercial serological assays are developed and are
88 now available in the market. A meta-analysis done on these serological assays for detecting
89 antibodies against SARS-CoV-2 have shown that assays using the S antigen and testing IgG
90 antibodies perform with better sensitivity than N antigen and Ig M based tests. [5]

91 It is important that we understand the strengths and limitations of commercially available
92 serological assays for better application for these tests to understand immune response and
93 the protection and duration of protection after vaccination. Hence this research tries to
94 evaluate the various methods for detecting SARS-CoV-2 antibodies compared to the gold
95 standard PRNT.

96 **Objective**

97 To evaluate the performances of commercially available serological assays for detecting
98 SARS-CoV-2 antibodies

99 **Methods**

100 The study compared six different methods for detection of antibodies against SARS-CoV-2
101 detection post vaccination for COVID-19 against the gold standard Plaque Reduction
102 Neutralization Test (PRNT). The six different methods are (i) Genscript SARS-CoV-2
103 surrogate virus neutralization test kit [Test A] (ii) Diasorin - SARS-CoV-2 S1/S2 IgG
104 detection [Test B] (iii) Alinity SARS-CoV-2 IgG II [Test C] (iv) Diasorin – SARS-CoV-2
105 TrimericS IgG [Test D] (v) Roche Elecsys Anti-SARS-CoV-2 – cobas [Test E] (vi)
106 AESKULISA (AESKU Enzyme Linked Immunosorbent Assay) [Test F]

107 The PRNT is a serological test which utilizes the ability of a specific antibody to neutralize a
108 virus, in turn, preventing the virus from causing the formation of plaques in a cell monolayer.
109 In this study, Vero E6 cells were grown to a confluent monolayer in a 6 well plate. The
110 positive control was (Pooled Serum sample of Vaccinated and/or Covid-19 positive patient)
111 and viral stock diluted in Dulbecco's modification of Eagle medium (DMEM) was used as
112 negative control.

113 Interpretation is based on 50% neutralization, which is the last dilution of serum capable of
114 inhibiting 50% of the total plaques (virions). Negative control should have plaque count \geq
115 50%, positive control should be plaque count \leq 50% of negative control, and titer at which
116 50% reduction of plaques is there in comparison to the negative control is taken as the
117 antibody titer. For positive PRNT results, the cut off for positive is 1:20 dilution.

118 The study was done on 125 samples, of which 69 stored de-identified excess serum samples
119 collected from post-vaccination patients who requested post-vaccination antibody testing for

120 antibody levels against SARS-CoV -2 Virus and 56 negative serum samples from non-
121 vaccinated COVID-19 negative patients. Each individual sample was tested using the PRNT
122 method and with all the six different serological assays, and the results of each method were
123 compared to the gold standard reference method which is PRNT.

124 All serological assays were done based on manufacturers' guidelines and recommendations.
125 Table 1 shows the details of the various serological assays evaluated in this study. Test A and
126 F were enzyme linked immunosorbent assay (ELISA) based tests, tests B,D and E were
127 chemiluminescent immunoassay (CLIA) based tests and test D was based on
128 chemiluminescent microparticle immunoassay (CMIA)

129 **Results**

130 125 samples were used in this study and PRNT was done on all 125 samples. Due to a lack of
131 sufficient sample volume, some of the serological assays were not performed for certain
132 samples. The borderline/equivocal results that were above the cut-off values for positive
133 reports were considered positive. Table 2 shows the number of samples tested using each
134 assay and the results of each.

135 Test E had the highest sensitivity followed by test C and F. Test A had the highest specificity
136 followed by test B and D. Test E though had the highest sensitivity had the lowest specificity
137 compared to the other rapid tests as shown in Table 3.

138 When the high sensitivity tests E and C were followed by serial testing with tests A and B
139 with high specificity, it improved specificity of the tests E and C with a lower sensitivity.
140 [Figure 1] and [Figure 2]

141 Also employing two tests with high specificity in parallel for example test A with test B or
142 test D, improved the sensitivity to 92% and 95% respectively, with only a slight loss in
143 specificity. [Table 4]

144 When a functional test like test A is combined with a quantitative test in parallel and serial
145 testing, it shows that test A in parallel testing with test B or test D has the optimum sensitivity
146 and specificity. (Table 4 and Table 5) Test A in serial testing with test B shows the maximum
147 specificity. (Table 5)

148 ROC curve was plotted for all the serological assays and the area under the curve was largest
149 for test D followed by test A and test B, showing the best performance to differentiate
150 positive and negative results compared to the PRNT results. (Figure 3 and Table 6)

151 Based on the ROC optimum cutoffs for the tests were estimated and these were similar to the
152 manufacturer's values for tests B and F. However, tests A, C, D and E showed different cut
153 offs based on our ROC curves than the one recommended by the manufacturers. From the
154 adapted ROC cut offs sensitivity, specificity, and overall agreement with the PRNT results
155 were calculated. [Table 7]

156 For test A, the manufacturers had an initial cut-off of 20% inhibition, which was changed
157 due to the FDA recommendations to 30% to increase specificity. However, comparing test A
158 results with the PRNT reports, showed 20% as optimum cut-off. The scatter plot of the
159 distribution of % inhibition of test A based on the PRNT reports show the number of positive
160 cases missed, with the increase in cut-off values by 10%. [Figure 4]

161 Test A showed higher sensitivity and overall agreement with PRNT when 20% inhibition was
162 used as a cut-off then the recommended 30%. [Figure 5]

163

164 **Discussion**

165 This study compared six immunoassays for detection of IgG antibodies against SARS-CoV-2
166 against the standard viral neutralization test PRNT.

167 In this study, tests A and B had the lowest sensitivity but had a high specificity and PPV. But
168 studies that evaluated test A had demonstrated test A to have high sensitivity [6,7]. However,
169 this might be because all these studies used cutoff as 20% inhibition, which was later changed
170 according to FDA recommendation to 30%. [8] A study that compared test A to PRNT
171 similar to our study used 30% as cutoff and showed that sensitivity ranged from 77% - 100%
172 and specificity was 95% - 100% [9], which was similar to our study results when 30% cutoff
173 was used.

174 The ROC curve adapted cutoff for test A was around 20% inhibition and when 20% was used
175 as a cutoff for test A the sensitivity increased to 92.31% and the overall agreement with the
176 PRNT results was better (90.4%) suggesting 20% inhibition as a more optimum cut off for
177 the test.

178 Another study that evaluated test A suggested that the test might require specific cutoffs with
179 respect to ethnic, geographical background and the prevalence of COVID-19 infections. The
180 study also showed that introduction of an equivocal range with repeat testing within the range
181 of 18 – 22% can reduce the false positive results.[10]

182 Based on the ROC threshold values, tests D and E did not correlate with the manufacturers
183 cut-off. Raising the cut-offs for tests D and E as per the ROC values showed increased
184 specificity and agreement with the PRNT results without much change in sensitivity.
185 However, for test C raising the cut-off increased specificity with a huge drop in sensitivity,
186 but the agreement with the PRNT results were better.

187 Studies suggest revision of cut- off values provided by manufacturers, as most of the assay
188 validation are done on a small sample size and among specific ethnic or regional group.[11]
189 Therefore more evaluation studies and optimum cut-offs need to be defined before these
190 serological assays are used in large scale to evaluate vaccination status of the population.

191 Test E had the highest sensitivity in this study as reported in similar studies, but these studies
192 have also reported high specificity, which our study did not find. [12,13]

193 The sensitivity of test B was similar to that reported in other studies [12]. Studies evaluating
194 C and E demonstrated higher specificity of test C and test E compared to our study. [14] A
195 meta-analysis on antibody tests for SARS-CoV-2 showed that tests using ELISA and CLIA-
196 based methods performed better [5]. In our study test A and F are based on ELISA and tests
197 B, D and E were CLIA-based tests. While tests D, E and F showed higher sensitivities, the
198 sensitivities of test A and B were low.

199 Test C was evaluated by a study which compared antibodies in post-vaccination patients
200 compared with pre-pandemic serum samples and claims high sensitivity and a specificity of
201 100%. While our study showed that the sensitivity of test C was high, the specificity was low
202 compared to this study. [15] This might be because these studies have not compared the
203 assays with the PRNT method, but with the RT-PCR assay validation.

204 Test D had good sensitivity and specificity with the highest agreement with the PRNT results,
205 as also supported by another that evaluated test D. [16]

206 In addition, when a functional test like test A was tested with quantitative tests in parallel, it
207 is observed that the overall sensitivity increases. An optimum sensitivity and specificity are
208 achieved when test A is done in parallel with test B. This kind of combination of two
209 antibody tests are being studied and it shows that it increases the ability to capture the
210 positive results. [17]

211 The CDC recommends serological tests with high sensitivity and specificity and tests
212 detecting IgG or both IgG and IgM. This is because currently serological tests are
213 recommended by CDC only for identifying persons with previous infections or to identify
214 resolving infections and for better understanding the epidemiology of SARS-CoV-2. [18]

215 However, these antibody tests help us understand the development of immune response and
216 the longevity of the antibodies developed post-vaccination for COVID-19. This surveillance
217 becomes essential to identify vaccine efficiency and make recommendation on booster doses
218 and the intervals for vaccination.

219 The WHO, in collaboration with Coalition for Epidemic Preparedness Innovations (CEPI),
220 and the National Institute for Biological Standards and Control (NIBSC), has come up with
221 the International standards for anti-SARS-CoV-2 immunoglobulins. This is very crucial for a
222 standard comparison as vaccine developers have been using various immunoassays with
223 different measuring units making the comparison of immunogenicity difficult. Hence with
224 these recommendations future studies can make the comparison of immunogenicity more
225 standardized and will be less challenging. [19]

226 Most COVID-19 vaccinations use the S protein or S-domains as immunogen target. [20]
227 Therefore these serological assays that target antibodies against S protein and the RBD
228 directed IgG detection serve as a good candidate for evaluating vaccine response. Therefore,
229 keeping this in mind, when serological assays are being used to assess post-vaccine immune
230 status, a balance of all parameters needs to be considered rather than emphasizing more on
231 only high specificity. This is particularly relevant in the current situation where vaccination is
232 happening around the globe and the percentage of vaccination is increasing, high sensitivity
233 assays will result in reporting a lower percentage of false negative reports. This will help
234 assess the immune status and avoids panic about lack of vaccine response. Thus,
235 recommendations based on a balance of all these parameters are needed.

236 **Strengths**

237 Most evaluation studies compare the serological assays with RT-PCR reports. This study is
238 one of its kind that compares commercial serological assays using the same serum sample

239 and by evaluating the results with the gold standard PRNT reports. Thus, this study reduces
240 the biases and provides a standard comparison.

241 **Limitations**

242 The number of samples were limited and additional parameters like days post vaccination and
243 the type of vaccine were not taken into consideration in this study, which could have
244 provided further insights on the serological assay performances.

245 **Conclusion**

246 Serological assays that are commercially available are very promising and show good
247 agreement with the standard PRNT results. We recommend further studies of these
248 serological assays with large number of samples, to understand more about the performance
249 of these assays. Moreover, performing two tests in parallel testing improves the sensitivity
250 and a better alternative to conventional PRNT, however cost-effective evaluations are needed
251 to recommend these. We suggest optimization of the cut offs values for these serological
252 assays considering the prevalence, ethnic and geographical variations. Recommendations
253 based on the balance of all performance indicators rather than just specificity will help in the
254 application of these serological assays in assessing post-vaccination status.

255 **Funding statement**

256 The study was not funded by any funding body, it was done in Biogenix lab as a part of
257 research.

258 **Ethics approval and consent to participate.**

259 The Ethics approval was obtained from Department of Health (DOH) Institutional review
260 board (IRB), Abu Dhabi. All methods were carried out in accordance with relevant guidelines
261 and regulations.

262 **Informed consent statement**

263 Informed consent was waived off by the Department of Health (DOH) Institutional review
264 board (IRB), Abu Dhabi.

265 **Data Availability**

266 The data is available with the corresponding author, Dr. Sally, Director of Biogenix G42 lab
267 and will be produced on request.

268 **Conflict of interest**

269 The authors declare that they have no conflict of interest regarding the publication of this
270 paper.

271 **References**

- 272 1. Bryant JE, Azman AS, Ferrari MJ, Arnold BF, Boni MF, Boum Y, Hayford K,
273 Luquero FJ, Mina MJ, Rodriguez-Barraquer I, Wu JT. Serology for SARS-CoV-2:
274 apprehensions, opportunities, and the path forward. *Science Immunology*. 2020 May
275 19;5(47).
- 276 2. Amanat F, Stadlbauer D, Strohmeier S, Nguyen TH, Chromikova V, McMahon M, et
277 al. A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nature*
278 *medicine*. 2020 Jul;26(7):1033-6.
- 279 3. Perera, R.A., Mok, C.K., Tsang, O.T., Lv, H., Ko, R.L., Wu, N.C., Yuan, M., Leung,
280 W.S., Chan, J.M., Chik, T.S. and Choi, C.Y., 2020. Serological assays for severe
281 acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March
282 2020. *Eurosurveillance*, 25(16), p.2000421.

- 283 4. Okba NM, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al.
284 Severe acute respiratory syndrome coronavirus 2-specific antibody responses in
285 coronavirus disease 2019 patients. *Emerg. Infect. Diseases*. 2020;26(7).
- 286 5. Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG. Antibody Tests in
287 Detecting SARS-CoV-2 Infection: A Meta-Analysis. *Diagnostics*. 2020; 10(5):319.
- 288 6. Puthachoen O, Wacharapluesadee S, Chia WN, Paitoonpong L, Tan CW,
289 Suwanpimolkul G, et al. Early detection of neutralizing antibodies against SARS-
290 CoV-2 in COVID-19 patients in Thailand. *PloS one*. 2021 Feb 12;16(2):e0246864
- 291 7. Müller K, Giral P, von Buttlar H, Dobler G, Wölfel R. Comparison of two commercial
292 surrogate ELISAs to detect a neutralising antibody response to SARS-CoV-2. *Journal*
293 *of Virological Methods*. 2021 Mar 8:114122
- 294 8. Food and Drug Administration (FDA). USA. cPass™ SARS-CoV-2 Neutralization
295 Antibody Detection Kit. Available at: <https://www.fda.gov/media/143583/download>.
296 (Accessed on 3/3/2021)
- 297 9. Papenburg J, Cheng MP, Corsini R, Caya C, Mendoza EJ, Manguiat KJ, et al.
298 Evaluation of a Commercial Culture-free Neutralization Antibody Detection Kit for
299 Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison with an
300 Anti-RBD ELISA Assay. *medRxiv*. 2021 Jan 1.
- 301 10. Bond K, Nicholson S, Lim SM, Karapanagiotidis T, Williams E, Johnson D, Hoang
302 T, Sia C, Purcell D, Mordant F, Lewin SR. Evaluation of serological tests for SARS-
303 CoV-2: Implications for serology testing in a low-prevalence setting. *The Journal of*
304 *infectious diseases*. 2020 Oct 15;222(8):1280-8.
- 305 11. Marzia N, Massimo P, Sandro G, Ciotti M, Miano R, Massimo A, Bernardini S.
306 SARS-CoV-2 infection serology: a useful tool to overcome lockdown?. *Cell Death*
307 *Discovery*. 2020;6(1).

- 308 12. Manthei DM, Whalen JF, Schroeder LF, Sinay AM, Li SH, Valdez R, Giacherio DA,
309 Gherasim C. Differences in performance characteristics among four high-throughput
310 assays for the detection of antibodies against SARS-CoV-2 using a common set of
311 patient samples. *American journal of clinical pathology*. 2021 Feb;155(2):267-79.
- 312 13. Wakita M, Idei M, Saito K, Horiuchi Y, Yamatani K, Ishikawa S, Yamamoto T,
313 Igawa G, Hinata M, Kadota K, Kurosawa T. Comparison of the clinical performance
314 and usefulness of five SARS-CoV-2 antibody tests. *Plos one*. 2021 Feb
315 8;16(2):e0246536.
- 316 14. Ainsworth M, Andersson M, Auckland K, Baillie JK, Barnes E, Beer S, Beveridge A,
317 Bibi S, Blackwell L, Borak M, Bown A. Performance characteristics of five
318 immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. *The Lancet*
319 *Infectious Diseases*. 2020 Dec 1;20(12):1390-400.
- 320 15. Narasimhan M, Mahimainathan L, Raj E, Clark AE, Markantonis J, Green A, et al.
321 Clinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative
322 IgG and IgM assays in infected, recovered, and vaccinated groups. *medRxiv*. 2021
323 Jan 1.
- 324 16. Bonelli F, Blocki FA, Bunnell T, Chu E, De La O A, Grenache DG, et al. Evaluation
325 of the automated LIAISON[®] SARS-CoV-2 TrimericS IgG assay for the detection of
326 circulating antibodies. *Clin Chem Lab Med*. 2021 Mar 12. doi: 10.1515/ccm-2021-
327 0023. Epub ahead of print. PMID: 33711225.
- 328 17. Schnurra C, Reiners N, Biemann R, Kaiser T, Trawinski H, Jassoy C. Comparison of
329 the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based
330 antibody tests. *J Clin Virol*. 2020 Aug;129:104544. doi: 10.1016/j.jcv.2020.104544.
331 Epub 2020 Jul 6. PMID: 32663788; PMCID: PMC7836838.

- 332 18. Center for Disease Control and Prevention (CDC). COVID-19. Interim guidelines for
 333 COVID-19 antibody testing. Available at: [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html)
 334 [ncov/lab/resources/antibody-tests-guidelines.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html) (Accessed on 3/3/2021)
- 335 19. Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, Plotkin S,
 336 Knezevic I. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. The
 337 Lancet. 2021 Mar 23.
- 338 20. Lee N, McGeer A. The starting line for COVID-19 vaccine development. The Lancet.
 339 2020 Jun 13;395(10240):1815-6.
- 340

341 **Table 1: Details of the six commercial serological assays**

Test	Reagent/kit	Method	Manufacturer	Isotype	Target protein	Run time (minutes)
A	cPass SARS-COV-2 surrogate virus neutralization test kit	ELISA	Genscript	IgG	RBD unit of S1	180
B	Diasorin SARS-CoV-2 S1/S2 IgG detection	CLIA	Diasorin	IgG	S1/S2	35
C	Alinity SARS-CoV-2 IgG II	CMIA	Abbott	IgG	RBD unit of S1	20
D	SARS-CoV-2 TrimericS IgG	CLIA	Diasorin	IgG	RBD unit of S1	20
E	Elecsys Anti-SARS-CoV-2 – cobas	CLIA	Roche	IgG & IgM	RBD unit of S1	20
F	AESKULISA (AESKU Enzyme Linked Immunosorbent Assay)	ELISA	AESKU	IgG	S1	180

342

343

344

345

346

347

348 **Table 2: Results of all six commercial serological assays.**

Assay	Positive	Negative	Total
Test A	52	73	125
Test B	43	61	104
Test C	67	37	104
Test D	50	53	103
Test E	76	20	96
Test F	61	38	99

349

350 **Table 3: Performance indicators of the serological assays compared to PRNT**

Assay	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)	Overall agreement with PRNT results (95% CI)
Test	71.07	94.64	94.23	72.60	81.6

A	(58.8–81.3)	(85.1-98.8)	(84.1-98.8)	(60.9-82.4)	(73.7-87.9)
Test	75.47	94.12	93.02	78.69	84.61
B	(61.7-86.2)	(83.8-98.8)	(80.9-98.5)	(66.3-88.1)	(76.2-90.9)
Test	98.11	70.59	77.61	97.30	84.62
C	(89.9-99.9)	(56.1-82.5)	(65.8-86.9)	(85.8-99.9)	(76.22-90.94)
Test	84.91	90	90	84.91	87.37
D	(72.4-93.2)	(78.1-96.6)	(78.1-96.6)	(72.4-93.2)	(79.4-93.1)
Test	100	41.67	63.16	100	70.83
E	(92.6-100)	(27.6-56.7)	(51.3-73.9)	(83.1-100)	(60.7-79.7)
Test	92.31	72.34	78.69	89.47	82.82
F	(81.5-97.9)	(57.4-84.4)	(66.3-88.1)	(75.2-97.1)	(73.9-89.7)

351

352 **Table 4: Test A in parallel testing with other serological tests**

Parallel testing		Sensitivity	Specificity
Test A	Test B	92.86	89.07
	Test C	99.46	66.80
	Test D	95.63	85.17
	Test E	100	39.72
	Test F	97.77	68.46

353

354 **Table 5: Test A in serial testing with other serological tests**

Serial testing		Sensitivity	Specificity
Test A	Test B	53.53	99.69

	Test C	69.65	98.41
	Test D	60.27	99.46
	Test E	71.0	96.9
	Test F	65.54	98.52

355

356

357 **Table 6: Area under the curve (AUC) for the serological assays**

358

Antibody tests	AUC	95% Confidence Interval
Test A	0.939	(0.888 - 0.990)
Test B	0.935	(0.885 - 0.986)
Test C	0.860	(0.784 - 0.936)
Test D	0.953	(0.912 - 0.994)
Test E	0.839	(0.751 - 0.927)
Test F	0.928	(0.871 - 0.984)

359

360 **Table 7: Optimum cut-offs based on the ROC curves and their performances.**

361

	Cut offs	Sensitivity	Specificity	Overall agreement with PRNT results
Test A	Manufacturer's cut off – 30%	71.0	94.23	81.6
	Based on ROC cut off – 20%	92.31	87.5	90.4
Test C	Manufacturer's cut off - 50	98.11	70.59	84.62


	Based on ROC cut off - 150	83.01	88.23	85.57
Test D	Manufacturer's cut off - 33.8	84.91	90	87.37
	Based on ROC cut off - 40	84.90	96.0	90.29
Test E	Manufacturer's cut off - 0.8	100	41.67	70.83
	Based on ROC cut off - 5	93.75	70.83	82.29

362 * Tests B and F showed ROC based cut offs similar to the manufacturer's values.

363

364


365 **Figure 1: Serial testing of test C with test A and test B**



366

367

368 **Figure 2: Serial testing of test E with test A and test B**




369

370

371

372

373 **Figure 3: ROC curves for the serological assays**




374

375

376

377 **Figure 4: Scatter plot of test A % inhibition based on results of the PRNT**

378



379


380

381

382 **Figure 5: Comparison of the test A performance based on two different cut-off values**

383

384



385

386

387